- Home
- BYSI vs BMEA Comparison
BYSI vs BMEA Comparison
Compare BYSI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- BMEA
- Stock Information
- Founded
- BYSI 2010
- BMEA 2017
- Country
- BYSI United States
- BMEA United States
- Employees
- BYSI N/A
- BMEA N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- BYSI Health Care
- BMEA Health Care
- Exchange
- BYSI Nasdaq
- BMEA Nasdaq
- Market Cap
- BYSI 72.1M
- BMEA 65.8M
- IPO Year
- BYSI 2017
- BMEA 2021
- Fundamental
- Price
- BYSI $1.63
- BMEA $1.67
- Analyst Decision
- BYSI
- BMEA Strong Buy
- Analyst Count
- BYSI 0
- BMEA 11
- Target Price
- BYSI N/A
- BMEA $27.60
- AVG Volume (30 Days)
- BYSI 32.8K
- BMEA 713.5K
- Earning Date
- BYSI 01-01-0001
- BMEA 05-05-2025
- Dividend Yield
- BYSI N/A
- BMEA N/A
- EPS Growth
- BYSI N/A
- BMEA N/A
- EPS
- BYSI N/A
- BMEA N/A
- Revenue
- BYSI N/A
- BMEA N/A
- Revenue This Year
- BYSI N/A
- BMEA N/A
- Revenue Next Year
- BYSI N/A
- BMEA N/A
- P/E Ratio
- BYSI N/A
- BMEA N/A
- Revenue Growth
- BYSI N/A
- BMEA N/A
- 52 Week Low
- BYSI $0.98
- BMEA $1.53
- 52 Week High
- BYSI $3.63
- BMEA $13.43
- Technical
- Relative Strength Index (RSI)
- BYSI 54.68
- BMEA 41.85
- Support Level
- BYSI $1.64
- BMEA $1.61
- Resistance Level
- BYSI $2.14
- BMEA $2.30
- Average True Range (ATR)
- BYSI 0.17
- BMEA 0.20
- MACD
- BYSI 0.03
- BMEA -0.00
- Stochastic Oscillator
- BYSI 50.60
- BMEA 21.74
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.